Menarini Asia-Pacific is just over a decade old, having established its regional headquarters in Singapore back in November 2011. Over the past decade, the island-nation’s positioning has changed from just a pharmaceutical manufacturing outpost to an international biomedical hub that encompasses the entire innovation and manufacturing value chain.
Globally, there remains an unmet need for advanced research in healthcare biotechnology and diagnostics. Singapore’s reputation for quality research and development (R&D), supportive operating environment, and talent pool made it an easy decision when deciding where to build our first diagnostics research arm in the world.
Menarini Biomarkers (A. Menarini Biomarkers Singapore Pte Ltd) was founded with the mission of identifying, developing, and validating new biomarkers on circulating human cells for applications in diagnostics.
There is a current healthcare gap in precision medicine surrounding the fields of early disease prediction and disease control, particularly related to precision rare-cell isolation, analysis, and disease diagnosis. Menarini Biomarkers uses single-cell analysis to provide clinicians with new tools for early detection, tracking disease progression, and the measurement of real-time responses to innovative therapies.
The R&D team specialises in pathogenic single-cell isolation that enables scientists to pinpoint specific disease markers, also known as biomarkers. The identification and selection of pathogenic single cells from blood samples is incredibly useful in disease treatment, as it helps healthcare practitioners narrow therapies down to target cells.
Pregnant women face complex healthcare journeys, undergoing different tests at various gestational stages and this does not necessarily include genetic testing. At the same time, an increasingly educated segment of the population wish to understand the potential health risks carried in their babies’ genes without undergoing invasive tests.
Last October, Menarini Biomarkers signed a Memorandum of Understanding with the SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI) to develop the first non-European based international medical hub for non-invasive testing in prenatal care.
The Biomarkers team have developed a technology that enables the isolation of rare cells taken from the blood of pregnant women. These rare cells are released from the unborn foetus and can provide the entire genome of a baby from the isolated foetal cells alone.
This patented technology can surpass any prenatal testing technology currently available in the market. It is a next-generation non-invasive clinical prenatal test (CB-NIPT) that can detect pathogenic microdeletions and microduplications in the foetal genome. The test can be conducted as early as the first trimester (10 weeks) to give an indication of potential diseases that can be treated in utero or immediately after birth. This avoids the crucial delay between disease discovery and treatment. Previously, in some cases, diseases were only formally diagnosed well into early childhood.
In the years to come, the team anticipates increased demand for CB-NIPT, owing to the rising average maternal age, as women choose to give birth later in life. Increased literacy rates, financial stability, and awareness of genome sequencing are also empowering women to demand access to world-class healthcare.
Beyond the SingHealth partnership, Menarini Biomarkers is also collaborating with the KK Women's and Children's Hospital, Singapore Eye Research Institute, and Singapore General Hospital to develop singlecell based diagnostic platforms for applications in the immuno-oncology field.
The team will continue to place strong emphasis on advancing highly specialised and scientifically valuable fields through close collaborations with academic and medical institutions to elevate the standard of healthcare not only in Asia, but globally.